Bicara Therapeutics (BCAX) Competitors $10.84 -0.73 (-6.31%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$10.90 +0.06 (+0.60%) As of 06/13/2025 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock BCAX vs. NAMS, BLTE, HRMY, KNSA, VCEL, DNLI, CGON, VERA, GMTX, and IMCRShould you be buying Bicara Therapeutics stock or one of its competitors? The main competitors of Bicara Therapeutics include NewAmsterdam Pharma (NAMS), Belite Bio (BLTE), Harmony Biosciences (HRMY), Kiniksa Pharmaceuticals (KNSA), Vericel (VCEL), Denali Therapeutics (DNLI), CG Oncology (CGON), Vera Therapeutics (VERA), Gemini Therapeutics (GMTX), and Immunocore (IMCR). These companies are all part of the "pharmaceutical products" industry. Bicara Therapeutics vs. Its Competitors NewAmsterdam Pharma Belite Bio Harmony Biosciences Kiniksa Pharmaceuticals Vericel Denali Therapeutics CG Oncology Vera Therapeutics Gemini Therapeutics Immunocore NewAmsterdam Pharma (NASDAQ:NAMS) and Bicara Therapeutics (NASDAQ:BCAX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, community ranking, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations. Does the MarketBeat Community prefer NAMS or BCAX? NewAmsterdam Pharma received 15 more outperform votes than Bicara Therapeutics when rated by MarketBeat users. Likewise, 91.18% of users gave NewAmsterdam Pharma an outperform vote while only 72.73% of users gave Bicara Therapeutics an outperform vote. CompanyUnderperformOutperformNewAmsterdam PharmaOutperform Votes3191.18% Underperform Votes38.82%Bicara TherapeuticsOutperform Votes1672.73% Underperform Votes627.27% Does the media prefer NAMS or BCAX? In the previous week, NewAmsterdam Pharma had 22 more articles in the media than Bicara Therapeutics. MarketBeat recorded 32 mentions for NewAmsterdam Pharma and 10 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 0.74 beat NewAmsterdam Pharma's score of 0.58 indicating that Bicara Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 10 Very Positive mention(s) 2 Positive mention(s) 12 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Bicara Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Which has preferable valuation and earnings, NAMS or BCAX? Bicara Therapeutics has lower revenue, but higher earnings than NewAmsterdam Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNewAmsterdam Pharma$47.14M48.13-$176.94M-$1.88-10.75Bicara TherapeuticsN/AN/AN/AN/AN/A Do analysts prefer NAMS or BCAX? NewAmsterdam Pharma currently has a consensus target price of $43.00, suggesting a potential upside of 112.77%. Bicara Therapeutics has a consensus target price of $31.86, suggesting a potential upside of 193.90%. Given Bicara Therapeutics' higher possible upside, analysts plainly believe Bicara Therapeutics is more favorable than NewAmsterdam Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NewAmsterdam Pharma 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Bicara Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is NAMS or BCAX more profitable? Company Net Margins Return on Equity Return on Assets NewAmsterdam PharmaN/A N/A N/A Bicara Therapeutics N/A N/A N/A Do institutionals and insiders hold more shares of NAMS or BCAX? 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 20.8% of NewAmsterdam Pharma shares are owned by insiders. Comparatively, 15.5% of Bicara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryNewAmsterdam Pharma beats Bicara Therapeutics on 6 of the 9 factors compared between the two stocks. Get Bicara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCAX vs. The Competition Export to ExcelMetricBicara TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$630.98M$6.88B$5.57B$8.50BDividend YieldN/A2.48%5.27%4.17%P/E RatioN/A8.4626.7519.65Price / SalesN/A261.91403.98152.07Price / CashN/A65.8538.2534.64Price / BookN/A6.526.964.59Net IncomeN/A$143.26M$3.23B$248.23M7 Day Performance-5.74%-0.21%-1.22%-1.07%1 Month Performance-25.09%10.62%6.34%2.59%1 Year PerformanceN/A3.63%33.05%13.50% Bicara Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCAXBicara Therapeutics2.0544 of 5 stars$10.84-6.3%$31.86+193.9%N/A$630.98MN/A0.0032Analyst RevisionNAMSNewAmsterdam Pharma2.9663 of 5 stars$18.93+4.5%$43.00+127.2%+5.3%$2.13B$47.14M-10.074Analyst ForecastAnalyst RevisionGap UpBLTEBelite Bio2.6268 of 5 stars$65.02+0.2%$96.67+48.7%+19.2%$2.07BN/A-58.5810Short Interest ↑Analyst RevisionHRMYHarmony Biosciences4.7702 of 5 stars$35.56+3.1%$53.00+49.0%+13.5%$2.04B$744.85M16.85200Positive NewsShort Interest ↑Analyst RevisionKNSAKiniksa Pharmaceuticals3.2361 of 5 stars$27.92+2.0%$38.80+39.0%+50.8%$2.04B$481.17M-199.41220Analyst UpgradeInsider TradeVCELVericel2.4662 of 5 stars$40.46-2.0%$61.14+51.1%+0.9%$2.04B$238.54M674.45300Positive NewsHigh Trading VolumeDNLIDenali Therapeutics4.3316 of 5 stars$13.96+5.4%$33.71+141.5%-29.8%$2.03B$330.53M-5.06430Positive NewsAnalyst RevisionGap DownHigh Trading VolumeCGONCG Oncology2.4419 of 5 stars$26.59+3.8%$58.22+119.0%-25.4%$2.03B$662K-17.6161Positive NewsAnalyst RevisionGap DownVERAVera Therapeutics2.8927 of 5 stars$31.74+67.5%$65.00+104.8%-36.9%$2.02BN/A-12.1640Short Interest ↑Analyst RevisionHigh Trading VolumeGMTXGemini TherapeuticsN/A$46.68-0.4%N/A+37.2%$2.02BN/A-46.6830News CoverageHigh Trading VolumeIMCRImmunocore3.0551 of 5 stars$38.65+5.6%$58.89+52.4%-9.8%$1.94B$333.58M-40.68320Positive NewsAnalyst UpgradeAnalyst RevisionHigh Trading Volume Related Companies and Tools Related Companies NAMS Competitors BLTE Competitors HRMY Competitors KNSA Competitors VCEL Competitors DNLI Competitors CGON Competitors VERA Competitors GMTX Competitors IMCR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCAX) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicara Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BCAX Stock Free BCAX Stock Alerts